Senmiao Technology Ltd (AIHS): Nasdaq/NYSE listing notice — Senmiao Technology receives Nasdaq delisting notice due to negative equity

Senmiao Technology Ltd

Stockholders' equity was ($132,073) as of Sept 30, 2025, below the $2.5M minimum.
Company has 45 days to submit a plan to regain compliance with Listing Rule 5550(b)(1).
If plan accepted, Nasdaq may grant extension to May 30, 2026 to evidence compliance.
Company intends to monitor equity and consider options; no immediate effect on listing.
Delisting could reduce liquidity, investor interest, and access to public capital markets.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Senmiao Technology Ltd received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

December 1, 2025, we received a letter from the listing qualifications staff (the “ Staff ”) of Nasdaq informing us that, as reported in our quarterly report on Form 10-Q for the period ended September 30, 2025, because our stockholders’ equity was ($132,073), as of September 30, 2025, we did not meet the alternatives of market value of listed securities or net income from continuing operations, and we no longer comply with the Listing Rule. We have 45 calendar days to submit a plan to the Staff to regain compliance. If our plan is accepted, we may be granted an extension of up to 180 calendar

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Senmiao Technology Ltd filing history →

Source: SEC EDGAR

accession 0001213900-25-119225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.